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TRANSLATIONAL IMMUNOLOGY IN KIDNEY DISEASE, ISN NEXUS SYMPOSIUM 2016binding to immobilized heparin-albumin, but not with albumin,
likely via MASP-1/2 – heparin interaction.
Conclusions: Our data identiﬁes small heparin-derived oligosac-
charide inhibitors speciﬁc for the LP. We show that the LP
inhibitory effect of GAGs is via blocking the enzymatic activity of
the MASP enzymes. Binding of the MBL-MASP complex to
immobilized heparin indicates that heparan sulfate/heparin struc-
tures on cells and in extracellular matrix in vivo might act as
docking platforms for the MBL-MASP complex. These results
might be important for renal diseases with LP involvement.
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Introduction: B cell depletion, most commonly with rituximab
(RTX), has emerged as a potential therapeutic strategy in SLE,
particularly in patients who are unresponsive to, or intolerant of,
standard therapy. Ofatumumab is a fully humanised anti-CD20
monoclonal antibody directed against distinct extra-cellular epitope
on CD20, which has shown efﬁcacy in the treatment of haemato-
logical malignancy. Since 2012, we have been using ofatumumab on
compassionate grounds in patients with SLE for whom B cell
depletion is deemed a desirable therapeutic approach, but who are
allergic to RTX.
Methods: This is a retrospective report of SLE cases treated with
ofatumumab at our centre between 2012-2015. Data are reported as
medians +/- IQR, and comparisons are by non-parametric testing,
unless otherwise stated.
Results: In total, 15 patients received ofatumumab: all female, mean
age 33 years, median duration of SLE 7.5 years (range 1-18). 46%
had previously been treated with cyclophosphamide and all had
previously received RTX (median time since last treatment 4.5
months). All had severe infusion reactions to RTX previously. Two
patients demonstrated infusions reactions to ofatumumab, such that
they did not receive full dosing and have therefore been excluded
from subsequent analysis.
Of the remaining 13 cases, ten were treated for disease ﬂares
complicated by lupus nephritis (LN); three patients were treated for
extra-renal disease. Our standard treatment protocol is ofatumumab
2x700mg iv doses, with MMF maintenance and minimal steroids.
Following treatment, two patients did not achieve B cell depletion
(BCC<20). In those who did deplete, the median time to depletion
was 16 days, and to subsequent reconstitution (BCC>20) 4.8
months (see Figure). Treatment was associated with signiﬁcant
improvements in serological markers of disease activity at 6 months
(see Figure & Table).Kidney International Reports (2016) 1, S1–S22At 0 months At 6 months p valueANA, titre (median+/-IQR) 2560 (240-2560) 320 (200-2080) 0.012dsDNA, iu (median+/-IQR) 331 (234-717) 132 (73-429) 0.001C3, g/L (median+/-IQR) 0.69 (0.52-0.99) 0.83 (0.65-1.10) 0.022C4, g/L (median+/-IQR) 0.12 (0.08-0.18) 0.14 (0.07-0.25) nsThree patients with LN did not respond to treatment (>1.5x
rise in serum creatinine at 6 months). The remaining patients
had stable renal function (<10% increase or improved serum
creatinine) with improved proteinuria (median uPCR 424 to
99 mg/mmol) at 6 months. At last followup (median duration
32months), no opportunistic infections, malignancies, new episodes
of hypogammaglobulinaemia, or deaths have been observed. Three
patients had further severe disease ﬂares requiring hospitalisation
and escalation of treatment.
Conclusions: In this heavily pre-treated cohort, with longstanding
SLE refractory to conventional treatment, ofatumumab was effec-
tive for B cell depletion in patients who were intolerant of ritux-
imab. Treatment was associated with serological and clinical
response, although a proportion of patients had progressive disease.
No unexpected safety signals were seen. Larger controlled studies
are desirable to further deﬁne the role of ofatumumab in the
treatment of SLE. Pending these studies, ofatumumab may be
considered for patients who are intolerant of RTX, and for whom B
cell depletion is still a desirable treatment strategy.
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Introduction: Cytomegalovirus (CMV) is a frequently encountered
opportunistic pathogen in renal transplant recipients (RTR). Spec-
trum of CMV infection ranges from latent infection to life-threat-
ening multisystem disease. Current KDIGO guidelines recommend
RTR to receive a biologic induction agent and all RTR (except in D-/
R- CMV serology) to receive chemoprophylaxis for CMV infection
with oral ganciclovir or valganciclovir for at least 3 months post
transplantation. Currently no guidelines exist for use of CMV
prophylaxis in patients transplanted without a biologic induction.S3
TRANSLATIONAL IMMUNOLOGY IN KIDNEY DISEASE, ISN NEXUS SYMPOSIUM 2016Aim: Primary: To study the incidence and mortality of CMV
disease (CMVD) in patients receivingno induction, before and after
universal prophylaxis.
Secondary: To study the clinical proﬁle of Early Versus Late
CMVD
Methods: Retrospective observational study. CMVD diagnosed
based on CMV DNA PCR/tissue histopathology in combination with
typical signs and symptoms.
Exclusion criteria: Age <18 years and patients who received
biologic agents as induction or in post-transplant period.
Study period: September 2013 – August 2015. All were ABO
compatible live renal transplant (RTx).
For analysis of Primary outcome, patients who received no in-
duction were divided into two groups: (I) All patients transplanted
after September 2014 received oral valganciclovir at a dose of
450mg O.D. for 100 days (UNIVERSAL PROPHYLAXIS GROUP)
(II) Patients transplanted before September 2014 received no
CMV chemoprophylaxis if they had not received induction with a
biologic agent.
All patients diagnosed with post RTx CMVD from September
2013 to August 2015 were included and divided into two groups for
analysis of Secondary outcome (A) Late CMV disease (>1yr post
RTx) (B) Early CMV disease (<1yr post RTx).
Results: 28 patients were included in the study (No induction
group). All had D+ / R+ CMV serology status pretransplant. Out of
12 patients in group (II), 5 developed CMVD (41.6%). 4 out of 5
patients with CMVD had expired (80%). Out of 16 patients in group
(I), no cases of CMVD were diagnosed and 1 patient out of 16 died
due to gram negative sepsis at the end of study period. A total of 8
patients were diagnosed with CMVD during the study period and
were included for secondary outcome analysis. 5 belonged to group
A and 3 to group B. The clinical proﬁle and outcomes are repre-
sented in Table 1.
Table 1.
Early CMVD Late CMVDS4No. of patients 5 3Immunosuppression TAC/MMF/Steroids CSA/AZA/SteroidsMean duration to
develop CMVD72 days post-transplant 8 yearsDisease
ManifestationsLeucopenia and opportunistic
infections (Disseminated
Strongyloidiasis and Nocardiosis)Tissue invasive disease
(CMV hepatitis, Gastritis
and retinitis)Mean CNI Levels Tac trough levels10.3ng/ml C2 levels 708mmol/LMean CMV copies 70,000 IU/ml 1054 IU/mlOutcomes 4/5 (80%) expired Responded well to
antivirals with good
patient outcomeConclusions: Incidence of CMVD was 41.6% with a high mortal-
ity(80%) in patients without universal CMV prophylaxis. Pro-
phylaxis with oral valganciclovir irrespective of induction/no
induction should be universalized to improve patient outcomes.
Early CMVD had a high incidence of life threatening opportunistic
infections resulting in poor patient outcomes versus patients with
late CMVD who had milder non-leucopenic tissue invasive CMVD
with better outcomes.
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Introduction: Chronic kidney disease (CKD) is one major medical
condition worldwide, which leads to signiﬁcant morbidity and
mortality. CKD patients have a signiﬁcant alteration in innate and
adaptive immune responses. Disturbance in innate immune re-
sponses in CKD patients has for example been represented by
dysfunction of neutrophil granulocytes as a consequence of chronic
activation leading to high levels of inﬂammatory cytokine. Given
the vital role of basophil cells in the pathogenesis of CKD; we aimed
to study the potential inﬂammatory response of basophils in
chronic kidney disease patients on hemodialysis.
Methods: The hemodialysis patients were recruited from the
Department of Nephrology at the Karolinska University Hospital in
Stockholm, Sweden. The estimated Glomerular Filtration Rate for
the patients was (eGFR) of <20 ml/min/1.73 m2 with a residual GFR
from 6-11. Patients were undergoing hemodialysis with polysulfone
high ﬂux dialyzers, three times per week for four to four and a half
hours per dialysis before the study (n¼10). Peripheral blood sam-
ples were drawn from patients before start of hemodialysis session.
The basophil surface expression of different activation markers
CD203c (basophil selection marker), CD63 (degranulation marker),
CD11b, active CD11b, CD62L (adhesive markers) and CD300a
(inhibitory marker of degranulation) were investigated, after
stimulation of different activation pathways in basophils with
Lipopolysaccharide (LPS), peptidoglycan (PGN), formyl-methyi-
noyl-leucyl-phenylalanine (fMLP), and anti- Fc RI antibody.
Results: The basophil expression of CD63 following activation by
fMLP was signiﬁcantly higher in the patient group compared to
healthy controls, but no differences were noted after activation by
anti-FcÉiRI-ab. CD300a expression was signiﬁcantly higher in pa-
tients following activation by fMLP and anti-FcÉiRI and the active
epitope CD11b expression was signiﬁcantly higher in patients after
LPS activation. In addition, we found that CD62L, in contrast with
that in neutrophils, was not shed from basophil surface after acti-
vation with LPS and fMLP but a signiﬁcant downregulation was
observed after activation with anti-FcÉiRI-ab in healthy controls.
Conclusions: In conclusion, these data show that basophil func-
tions related to adhesion and degranulation are altered in CKD
patients which indicate a potential role for the basophil in the
pathogenesis of CKD.
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Introduction: Persistent viral hepatitis C (HCV) is the main reason
for chronic liver diseases in patients on hemodialysis (HD). The ﬂow
of infectious process in this patients’ category has important dis-
tinctions. With chronic infections, the virus has a true mutagenic
effect.
The object of the present research was to study the level of
mutation variability in peripheral blood lymphocytes of patientsKidney International Reports (2016) 1, S1–S22
